This is a partially double-blinded, multi-center, randomized, controlled
superiority study to evaluate the potential benefits of intensified surveillance
versus standard surveillance in medium-risk and high-risk early breast cancer
patients.
3500 patients will be randomized in a 1:1 ratio after completion of primary anti-tumor therapy (adjuvant chemotherapy, surgery or radiotherapy, whichever
occurs last) to receive:
- Standard Surveillance according to national guidelines or
- Intensive Surveillance
This is a partially double-blinded, multi-center, randomized, controlled
superiority study to evaluate the potential benefits of intensified surveillance
versus standard surveillance in medium-risk and high-risk early breast cancer
patients.
3500 patients will be randomized in a 1:1 ratio after completion of primary anti-tumor therapy (adjuvant chemotherapy, surgery or radiotherapy, whichever
occurs last) to receive:
- Standard Surveillance according to national guidelines or
- Intensive Surveillance
